Paralysis-free survival after treatment with lumiliximab, rituximab, fludarabine, and lumiliximab plus rituximab or lumiliximab plus fludarabine in a disseminated lymphoma mouse model. (A) On day 0, groups of mice (n = 10) were inoculated intravenously with 4 × 106 SKW6.4 cells. Mice in the rituximab or lumiliximab single-agent groups were given 200 μg or 400 μg of lumiliximab. Mice in the control group were given 400 μg isotype control antibody. Antibody injections were given on days 1, 3, 5, 7, 9, and 11 after tumor inoculation. (B) On day 0, groups of mice (n = 10) were inoculated intravenously with 3.6 million SKW6.4 cells. Mice in the lumiliximab single-agent group received 200 μg of lumiliximab intraperitoneally on days 3, 7, 11, and 15. (B) Mice in the rituximab group were given 200 μg of rituximab. Mice in the combination group were injected intraperitoneally with 200 μg each of lumiliximab and rituximab. (C) Mice in the fludarabine group were given 50 mg/kg on day 5 and day 10 after tumor inoculation. Mice in the combination group were injected intraperitoneally with 200 μg of lumiliximab and 50 mg/kg fludarabine according to the regimen described here. Mice in the control group were given 200 μg isotype control antibody according to the regimen described here. Antitumor response in this model is defined as “% Paralysis-free survival,” which represents the fraction of animals surviving without terminal paralysis or severe disease.
